Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bce17a68e3def6e8cf173f92eb55ce95 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4960a8840db73502e4d95c961ddf9c0c |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-577 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0648 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-064 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
filingDate |
2015-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf0eb8bb020a6866f78c537195b4ee6b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70a4b5d2d8f28aef99d03ed936c44f87 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e5770d39abda4d241c49faadd68392c |
publicationDate |
2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-10561685-B2 |
titleOfInvention |
Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system |
abstract |
This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially. |
priorityDate |
2014-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |